Analytical Data
-
Gene name
SLC1A1
- Application
-
Alternative Names
SLC1A1；EAAC1；EAAT3；HEAAC1；Excitatory amino acid transporter 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43005
-
Expression Region
430-524aa
-
AA Sequence
AEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVNIVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF
-
Molecular Weight
37.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC1A1, a member of the solute carrier family, encodes a high-affinity neurotransmitter transporter primarily responsible for the uptake of glutamate in the central nervous system. Dysregulation of glutamate homeostasis is linked to various neurological disorders, including epilepsy, schizophrenia, and neurodegenerative diseases. As the primary excitatory neurotransmitter, glutamate plays a crucial role in synaptic transmission, plasticity, and overall brain function. Given the importance of SLC1A1 in maintaining glutamatergic signaling, researchers have focused on characterizing its structure and function through the study of recombinant SLC1A1 proteins. These recombinant proteins offer a valuable tool for elucidating the transporter’s mechanism of action, its interaction with various substrates and inhibitors, and its role in synaptic dynamics. Additionally, understanding the molecular basis of SLC1A1 function can provide insights into how alterations in its activity contribute to neuronal excitability and pathophysiology of mental disorders. Furthermore, the development of targeted pharmacological agents that modulate SLC1A1 activity has the potential to pave the way for novel therapeutic strategies to treat glutamate-related conditions. Overall, the study of recombinant SLC1A1 proteins represents a critical avenue in neurobiology, enabling researchers to dissect the complexities of glutamate transport and its implications for brain health and disease.
